Key facts
- This page summarizes Jennifer Lynne Fox's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Mar 2024, 17:16.
Jennifer Lynne Fox - 13 Mar 2024 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- EVP, Ext Aff, GC, Corp Sec
- Issuer ticker
- EBS
- Reported as of
- 13 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Mar 2024, 17:16:03 UTC
- Prior SEC filing
- 04 Mar 2024
- Next SEC filing
- 11 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Lynne Fox, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jennifer Lynne Fox filed Form 4 for Emergent BioSolutions Inc. (EBS) on 15 Mar 2024.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EBS
transaction
Derivative
Employee Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- +127%
- Price
- $0.000000
- Shares after
- 223,169
- Date
- 13 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $2.33
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Vests in three equal installments beginning on the day prior to the anniversary date of the grant.